

Amendment




Please amend the claims as follows:

Please cancel claims 67-165 and add the following claims:

-166. A method to identify an immunogenic peptide consisting of about 8-11 amino acid residues that induces a cytotoxic T cell response restricted by at least three alleles selected from the group consisting of B0701, B1401, B3501, B3503, B5101, B5301, B5401, Cw0602 and Cw0601 which method comprises

- a) providing an amino acid sequence of an antigen of interest:
- b) locating within said sequence a subsequence of 8-11 amino acid residues which sequence comprises a first anchor residue at position 2 of said subsequence which is P, and a second anchor residue at the carboxy terminus of said subsequence selected from the group consisting of V, I, L, F, M, W, Y and A;
- c) preparing one or more fragments of said antigen of interest that consist essentially of said located subsequence;
- d) testing *in vitro* a first complex of said one or more fragments and a first HLA molecule selected from the group set forth above for recognition by cytotoxic T cells to induce a cytotoxic T cell response; and
- e) testing *in vitro* at least a second complex of said fragment tested in (d) with at least a second HLA molecule different from the HLA molecule used in (d) and selected from the group set forth above for recognition by cytotoxic T cells so as to induce a cytotoxic T cell response; and
- f) testing *in vitro* at least a third complex of said fragment tested in (d) and (e) with at least a third HLA molecule different from the HLA molecules used in (d) and (e) and selected from the group set forth above for recognition by cytotoxic T cells so as to induce a cytotoxic T cell response; and



selecting at least one fragment which elicits a cytotoxic T cell response in all of

The method of claim 166 wherein said second anchor residue is selected from the group consisting of V, I, F, M, W, Y, and A.

- The method of claim 166 or 167 wherein said antigen of interest is HER2/neu; 168. p53; a MAGE antigen; a prostate antigen; and HPV antigen; an HIV antigen; an HBV antigen; and HCB antigen; or a malaria antigen.
 - The method of claim 168 wherein the antigen is a p53 antigen. 169.
 - The method of claim 169 wherein said fragment is APAPAPSWPL. 170.
 - A method to identify an immunogenic peptide consisting of about 8-11 amino 171. acid residues that induces a cytotoxic T cell response restricted by at least three alleles selected from the group consisting of B0701, B1401, B3501, B3503, B5101, B5301, B5401, Cw0602 and Cw0601 which method comprises
 - providing an amino acid sequence of an antigen of interest: a)
- locating within said sequence a subsequence of 8-11 amino acid residues which b) sequence comprises a first anchor residue at position 2 of said subsequence which is P, and a second anchor residue at the carboxy terminus of said subsequence selected from the group consisting of V, I, L, F, M, W, Y and A;
 - preparing one or more fragments of said antigen of interest that consist essentially c) of said located subsequence;
 - testing in vitro the ability of said one or more fragments to bind to a first HLA d) molecule selected from the group set forth above with an IC_{50} less than 500nM; and

3

Serial No. 08/452,843 Docket No. 399632001321

- e) testing *in vitro* the ability of said fragment tested in (d) to bind at least a second HLA molecule different from the HLA molecule used in (d) and selected from the group set forth above with an IC₅₀ of less than 500nM; and
- f) testing *in vitro* the ability of said fragment tested in (d) and (e) to bind at least a third HLA molecule different from the HLA molecules used in (d) and (e) and selected from the groups set forth above with an IC₅₀ of less than 500nM; and
- g) selecting at least one fragment which binds with an IC_{50} less than 500nM in all of (d), (e) and (f).
- 172. The method of claim 171 wherein said second anchor residue is selected from the group consisting of V, I, F, M, W, Y, and A.
- 173. The method of claim 171 or 172 wherein said antigen of interest is HER2/neu; p53; a MAGE antigen; a prostate antigen; and HPV antigen; an HIV antigen; an HBV antigen; and HCB antigen; or a malaria antigen.
 - 174. The method of claim 173 wherein the antigen is a p53 antigen.
 - 175. The method of claim 174 wherein said fragment is APAPAPSWPL.